%0 Journal Article
%T Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study
%A Niina Siitonen
%A Leena Pulkkinen
%A Jaana Lindstr£¿m
%A Marjukka Kolehmainen
%A Johan G Eriksson
%A Mika Venoj£¿rvi
%A Pirjo Ilanne-Parikka
%A Sirkka Kein£¿nen-Kiukaanniemi
%A Jaakko Tuomilehto
%A Matti Uusitupa
%J BMC Medical Genetics
%D 2011
%I BioMed Central
%R 10.1186/1471-2350-12-5
%X Participants in the Finnish Diabetes Prevention Study were randomly assigned to a lifestyle intervention group or a control group. Those whose DNA was available (n = 507) were genotyped for ten ADIPOQ single nucleotide polymorphisms (SNPs). Associations between SNPs and baseline body weight and serum adiponectin concentrations were analysed using the univariate analysis of variance. The 4-year longitudinal weight data were analysed using linear mixed models analysis and the change in serum adiponectin from baseline to year four was analysed using Kruskal-Wallis test. In addition, the association of SNPs with the risk of developing T2DM during the follow-up of 0-11 (mean 6.34) years was analysed by Cox regression analysis.rs266729, rs16861205, rs1501299, rs3821799 and rs6773957 associated significantly (p < 0.05) with body weight at baseline and in the longitudinal analyses. The rs266729 C allele and the rare minor alleles of rs2241766 and rs2082940 were associated with an increased adjusted hazard ratio of developing T2DM. The differences in baseline serum adiponectin concentrations were seen according to rs16861210, rs17366568, rs2241766, rs6773957 and rs2082940 and differences in the change of serum adiponectin levels from baseline to the four year examination were seen according to rs16861205, especially in subjects who were able to lose weight during the first year of intervention.These results from the Finnish Diabetes Prevention Study support the concept that genetic variation in ADIPOQ locus contributes to variation in body size and serum adiponectin concentrations and may also modify the risk of developing T2DM.ClinicalTrials.gov NCT00518167Type 2 diabetes (T2DM) and obesity are increasing worldwide. Although this is mainly due to environmental factors, such as changes in diet and lifestyle, much evidence for genetic predisposition to these complex traits exist [1].Adiponectin is an adipokine, and its plasma levels are decreased in obesity [2], T2DM [3], ins
%U http://www.biomedcentral.com/1471-2350/12/5